Transitional CareTRAJNCT07079943
TRAJ : Transition in Rheumatology, From Adolescence to Adulthood
A study testing Self-questionnaire : satisfaction and quality of life and Self-reported questionnaire : educational or professional in people with Transitional Care, run by University Hospital, Bordeaux at 1 site in France.
Trial summary
This study evaluates the impact of the CAPAdJA transition support program on care continuity for young patients with chronic rheumatic diseases at Bordeaux University Hospital. The primary objective is to compare the proportion of patients lost to follow-up six months after the transition consultation between those… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Transitional Care
- What is being tested?
- Self-questionnaire : satisfaction and quality of life and Self-reported questionnaire : educational or professional
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- Jul 2025to Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who benefited from a pediatric-to-adult rheumatology transition consultation at Bordeaux University Hospital between 2017 and 2024
- Patients over 18 years old at the time of completing the self-administered questionnaire.
Who cannot join
- Patients who do not speak French
- Patients who have refused to participating
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Julie PERROT, MD contact
France1 site
CHU de Bordeaux
Bordeaux
Olivier RICHER, MD, +335 57 82 28 28, olivier.richer@chu-bordeaux.fr
About this study
Official title: From Adolescence to Adulthood : Analysis of the Impact of the CAPADJA Transition Support Program in Rheumatology at Bordeaux University Hospital
This study evaluates the impact of the CAPAdJA transition support program on care continuity for young patients with chronic rheumatic diseases at Bordeaux University Hospital. The primary objective is to compare the proportion of patients lost to follow-up six months after the transition consultation between those who benefited from CAPAdJA and those who did not.
Read the detailed description
The transition from pediatric to adult healthcare is a critical period for young patients with chronic diseases. This period carries risks such as disruptions in continuity of care, worsening symptoms, and a deterioration in quality of life. To address these challenges, transition support programs have been developed, including the CAPAdJA program, implemented in 2017 at Bordeaux University Hospital. While such programs seem to play a key role in structuring the transition process, their impact on care continuity and patient satisfaction remains poorly documented. The primary objective of this study is to assess the impact of the CAPAdJA program on the proportion of young patients lost to follow-up. Patients included six months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. The secondary objectives are to provide an overview of the medical and demographic characteristics of the transition in rheumatology at Bordeaux University Hospital and to analyze the impact of CAPAdJA on patient satisfaction and quality of life. Demographic and medical data will be collected using Dxcare. Then, patients will be categorized into two groups: those who benefited from the CAPAdJA support program and those who did not. Investigators will then compare the proportion of patients lost to follow-up in each group, as well as their responses to self-administered questionnaires focusing on quality of life and patient satisfaction.
- Conditions
- Transitional Care
- Being tested
- Self-questionnaire : satisfaction and quality of life, Self-reported questionnaire : educational or professional
- Keywords
- Transitional care, Lost to follow up, Patient-reported experience, Quality of life, Patient satisfaction
- Medical subject headings
- Patient Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-questionnaire : satisfaction and quality of lifeOther
Patient satisfaction and quality of life outcomes assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
Self-reported questionnaire : educational or professionalOther
Patient educational or professional outcomes, assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
| Study group | Role | What they receive |
|---|---|---|
| CAPAdJA group and Non-CAPADJA group | Other | Patients who benefited from pediatric-to-adult rheumatology transition consultation at Bordeaux University Hospital between 2017 and 2024 (Patients included 6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not) Receives: Other: Self-questionnaire : satisfaction and quality of life; Other: Self-reported questionnaire : educational or professional |
What is being measured
The primary outcome is the main question the study is designed to answer.
Follow-up patient
The primary endpoint is the proportion of patients lost to follow-up 6 months after the transition consultation, considered to be an indicator of continuity of care and, by extension, of the medical success of the transition. This criterion will be evaluated by examining the presence or absence of follow-up consultations in the adult rheumatology department, as recorded in the CHU consultation software, six months after the transition appointment.
Measured: six months after the transition appointment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2025
- Study startJul 2025 (estimated)
- Primary completionOct 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transitional CareStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Olivier RICHER, MD, Principal investigator, University Hospital, Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07079943
- Sponsor's protocol ID
- CHUBX 2025/007
- Acronym
- TRAJ
- Status last verified
- Jul 2025
- First submitted
- 23 Jun 2025
- Last updated
- 23 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- From Adolescence to Adulthood : Analysis of the Impact of the CAPADJA Transition Support Program in Rheumatology at Bordeaux University Hospital
- ClinicalTrials.gov ID
- NCT07079943
- Acronym / sponsor ID
- TRAJ / CHUBX 2025/007
- Conditions
- Transitional Care
- Keywords
- Transitional care, Lost to follow up, Patient-reported experience, Quality of life, Patient satisfaction
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- Jul 2025 (estimated)
- Primary completion
- Oct 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 23 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the impact of the CAPAdJA transition support program on care continuity for young patients with chronic rheumatic diseases at Bordeaux University Hospital. The primary objective is to compare the proportion of patients lost to follow-up six months after the transition consultation between those who benefited from CAPAdJA and those who did not.
Detailed description
The transition from pediatric to adult healthcare is a critical period for young patients with chronic diseases. This period carries risks such as disruptions in continuity of care, worsening symptoms, and a deterioration in quality of life. To address these challenges, transition support programs have been developed, including the CAPAdJA program, implemented in 2017 at Bordeaux University Hospital. While such programs seem to play a key role in structuring the transition process, their impact on care continuity and patient satisfaction remains poorly documented. The primary objective of this study is to assess the impact of the CAPAdJA program on the proportion of young patients lost to follow-up. Patients included six months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. The secondary objectives are to provide an overview of the medical and demographic characteristics of the transition in rheumatology at Bordeaux University Hospital and to analyze the impact of CAPAdJA on patient satisfaction and quality of life. Demographic and medical data will be collected using Dxcare. Then, patients will be categorized into two groups: those who benefited from the CAPAdJA support program and those who did not. Investigators will then compare the proportion of patients lost to follow-up in each group, as well as their responses to self-administered questionnaires focusing on quality of life and patient satisfaction.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CAPAdJA group and Non-CAPADJA group | Other | Other: Self-questionnaire : satisfaction and quality of life, Other: Self-reported questionnaire : educational or professionalPatients who benefited from pediatric-to-adult rheumatology transition consultation at Bordeaux University Hospital between 2017 and 2024 (Patients included 6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients who benefited from a pediatric-to-adult rheumatology transition consultation at Bordeaux University Hospital between 2017 and 2024
- Patients over 18 years old at the time of completing the self-administered questionnaire.
Key exclusion criteria (2 listed)
- Patients who do not speak French
- Patients who have refused to participating
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-questionnaire : satisfaction and quality of lifePatient satisfaction and quality of life outcomes assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. ) | Other | CAPAdJA group and Non-CAPADJA group |
| Self-reported questionnaire : educational or professionalPatient educational or professional outcomes, assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. ) | Other | CAPAdJA group and Non-CAPADJA group |
Primary outcome
Follow-up patient
Time frame: six months after the transition appointment
The primary endpoint is the proportion of patients lost to follow-up 6 months after the transition consultation, considered to be an indicator of continuity of care and, by extension, of the medical success of the transition. This criterion will be evaluated by examining the presence or absence of follow-up consultations in the adult rheumatology department, as recorded in the CHU consultation software, six months after the transition appointment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Transitional Care
Recruiting
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
Liver Diseases
RecruitingPhase 3
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Enrolling by invitation
BETTER (Brain Injury Education, Training, and Therapy to Enhance Recovery)
Traumatic Brain Injury
Active, not recruitingPhase 3
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Active, not recruitingPhase 2
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Julie PERROT, MD contact
Olivier RICHER, MD principal investigator
University Hospital, Bordeaux
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Self-questionnaire : satisfaction and quality of life and Self-reported questionnaire : educational or professional in people with Transitional Care, run by University Hospital, Bordeaux at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olivier RICHER, MD (+335 57 82 28 28, olivier.richer@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Follow-up patient (time frame: six months after the transition appointment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2025.